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Abstract
AIM
To evaluate long-term endoscopic resolution and recur-
rence rate of gastric antral vascular ectasia (GAVE) after 
argon plasma coagulation (APC) treatment.
METHODS
This was an IRB-approved retrospective single center 
study that included patients endoscopically treated for 
GAVE between 1/1/2008 to 12/31/2014. The primary 
and secondary end points of the study were rate of 
endoscopic resolution of GAVE after APC treatment and 
recurrence rate of GAVE after endoscopic resolution, 
respectively. Endoscopic resolution of GAVE was defined 
as no endoscopic evidence of GAVE after treatment with 
APC. Recurrence of GAVE was defined as endoscopic 
reappearance of GAVE after prior resolution.
RESULTS
Twenty patients met the study criteria. Median age 
(range) of the patients was 59.5 years (42-74 years). 
GAVE was associated with underlying cirrhosis in 16 
(80%) patients. Indications for initial esophagogastro-
duodenoscopy (EGD) included hematemesis and/or 
melena (9/20, 45%), iron deficiency anemia (6/20, 30%), 
screening or surveillance of varices (4/20, 20%), and 
occult gastrointestinal bleeding (1/20, 5%). The patients 
were treated with a total of 55 APC sessions (range 1-7 
sessions). Successful endoscopic resolution of GAVE was 
Retrospective cohort study
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achieved in 8 out of 20 patients (40%). There was no 
correlation between number of treatment sessions and 
GAVE treatment success (P  = NS). Recurrence of GAVE 
was noted on a subsequent EGD in 2 out of 8 patients 
(25%) with prior endoscopic resolution of GAVE. Median 
follow-up period for the study population was 627 d 
(range 63-1953 d).
CONCLUSION
Endoscopic resolution rate of GAVE was low (40%) with 
a 25% recurrence rate after treatment with APC. These 
rates suggest that APC treatment of GAVE may not be 
optimal in many circumstances. 
Key words: Gastric antral vascular ectasia; Argon plasma 
coagulation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Argon plasma coagulation (APC) has a 
good short-term success rate (> 80%) in improving 
symptoms related to gastric antral vascular ectasia 
(GAVE). However, GAVE related symptoms can recur in 
up to 50% of patients. This is the first study to evaluate 
resolution of GAVE after treatment with APC and its 
recurrence after successful treatment. The study showed 
a 40% resolution rate of GAVE after serial treatment 
with APC. The resolution of GAVE was not associated 
with number of APC sessions. GAVE was noted to recur 
in 25% of cases after successful resolution. These 
results suggest that APC may not be the best modality 
for treatment of symptomatic GAVE.
Garg S, Aslam B, Nickl N. Endoscopic resolution and recurrence 
of gastric antral vascular ectasia after serial treatment with 
argon plasma coagulation. World J Gastrointest Endosc 2017; 
9(6): 263-266  Available from: URL: http://www.wjgnet.
com/1948-5190/full/v9/i6/263.htm  DOI: http://dx.doi.
org/10.4253/wjge.v9.i6.263
INTRODUCTION
Gastric antral vascular ectasia (GAVE) is a well-defined 
clinical entity characterized endoscopically by prominent 
flat or erythematous streaks radiating in a spoke-like 
fashion from the pylorus to the antrum and pathologically 
by spindle cell proliferation in the mucosal blood vessels, 
intravascular fibrin thrombi and fibrinohyalinosis[1]. It is 
associated with portal hypertension or other systemic 
diseases like systemic sclerosis, and typically presents 
clinically as iron deficiency anemia and/or overt gastro-
intestinal (GI) bleeding[2]. In various case series, argon 
plasma coagulation (APC) has been shown to have > 
80% success for treatment of GAVE related anemia 
or GI bleeding[1-6]. However, these results have not 
been uniformly confirmed; Boltin et al[7], for example, 
reported a lower success rate (25.8%) of APC in treating 
GAVE related anemia or GI bleeding at a mean follow 
up period of 46.8 mo. Similarly in a recent systemic 
review, Swanson et al[8] reported a 44%-50% failure 
rate of APC in the treatment of anemia or GI bleeding 
related to GAVE. They concluded that there is very low 
quality evidence for the use of APC in the treatment 
of GAVE. A possible reason for this observation is that 
APC is used for controlling GAVE related symptoms but 
not for complete eradication of GAVE itself. None of the 
prior studies have evaluated endoscopic resolution of 
GAVE after APC therapy. This study was undertaken to 
evaluate endoscopic resolution and recurrence rate of 
GAVE after therapy with APC.
MATERIALS AND METHODS
This was an IRB-approved retrospective study. Cases 
were identified by reviewing billing data for the period 
January 1, 2008 - December 31, 2014 to identify all 
patients who had an EGD (CPT codes 43200 - 43259 
excluding 6 codes for EUS) at University of Kentucky 
Medical Center and with a billing diagnosis of GAVE 
(ICD-9 code 537.82). The diagnosis of GAVE was made 
endoscopically in each case.
The primary end point of the study was rate of 
endoscopic resolution of GAVE after APC treatment as 
seen on additional endoscopic exams subsequent to 
the index (first) exam which included treatment. The 
secondary end point of the study was GAVE recurrence 
rate after endoscopic resolution. Endoscopic resolution 
of GAVE was defined as no endoscopic evidence of GAVE 
after at least 1 treatment session with APC. Recurrence 
of GAVE was defined as endoscopic reappearance of 
GAVE on a subsequent EGD after successful resolution. 
Patients who did not undergo an APC session and at 
least one follow-up endoscopy, or had treatment of 
GAVE by a method other than APC were excluded from 
further analysis. The following information was collected 
from each patient’s medical record: Demographics, 
etiology of GAVE, indication and date of endoscopy(s), 
endoscopic findings, adverse effects during endoscopy, 
follow-up period and death.
Treatment for GAVE at this institution did not follow 
a standardized protocol, but was instead directed by 
individual physician and patient preference according 
to the clinical circumstances. GAVE was treated with 
APC during the initial endoscopy when it was assessed 
to be the cause of patient’s symptoms. Treatment of 
GAVE was repeated according to physician preference, 
generally every 4-8 wk; but not all patients underwent 
subsequent treatments. Procedures were done under 
appropriate sedation or anesthesia. APC treatment was 
performed using a high-frequency electrosurgical ERBE 
generator coupled to an argon gas delivery unit. The 
settings used for APC treatment were 20-60 Watts of 
power and 0.3 to 2 L/min of argon gas flow rate. In each 
APC session, affected areas were coagulated as much as 
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statistical analysis
Categorical data were described in fractions or per-
centages, and analyzed using Fischer’s exact or χ 2 
test depending on sample size. Continuous data were 
described as mean or median, and analyzed using 
t test or Wilcoxon rank-sum test depending on the 
distribution. Multivariate logistic regression was used 
to analyze the relationship between number of APC 
sessions and resolution of GAVE with APC. Two-sided 
p value of ≤ 0.05 was considered significant. The data 
were analyzed using STATA 13.1 (Statacorp® Texas).
RESULTS
A total of 45 patients with GAVE were identified by 
the initial screen for review. Twenty five patients were 
excluded from the final analysis: 8 patients did not get 
any treatment, 14 patients did not have a follow up 
EGD, and 3 patients had treatment of GAVE by other 
modalities. Twenty patients were included in the final 
analysis (Table 1). Median age (range) at the time of 
first EGD was 59.5 years (42-74 years). Ten patients 
were males (50%) and all the patients were Caucasians. 
GAVE was associated with underlying cirrhosis in 16 
(80%) patients.
Indications for initial EGD were hematemesis and/or 
melena (9/20, 45%), iron deficiency anemia (6/20, 
30%), screening or surveillance of varices (4/20, 20%), 
and occult gastrointestinal bleeding (1/20, 5%). A total 
of 55 APC sessions were done for the treatment of 
GAVE (2.75 sessions per patient, range 1-7 sessions). 
Successful endoscopic resolution of GAVE was achieved 
in 8 out of 20 patients (40%, 95%CI: 19%-64%). In all 
these 8 patients, GAVE was associated with underlying 
cirrhosis whereas none of the patients without cirrhosis 
had endoscopic resolution of GAVE. However, this 
difference was not statistically significant (p = 0.12). 
There was no correlation between number of treatment 
sessions and GAVE treatment success (p = 0.33, Table 
2). In 2 out of 8 patients (25%, 95%CI: 3%-65%) 
who had endoscopic resolution of GAVE, it was noted 
again on a subsequent EGD that was performed for 
a different indication. Median follow-up period for the 
study population was 627 d (range 63-1953 d).
Portal hypertensive gastropathy (PHG) was noted in 
3 out of 16 (18.75%) patients with GAVE and cirrhosis. 
GAVE resolution with APC treatment was noted in 2 
of these 3 patients with PHG. PHG was not noted in 
patients with recurrence of GAVE after initial resolution. 
No endoscopy related adverse events were found during 
the study period. Three patients (15%) died during the 
follow-up period. Time to death ranged from 123-986 
d. None of the deaths were related to the endoscopy or 
symptoms related to GAVE.
DISCUSSION
This is the first study to evaluate endoscopic resolution 
of GAVE and its recurrence rate after APC therapy. 
In this study, APC had a low success rate (40%) for 
endoscopic resolution of GAVE, with recurrence of GAVE 
seen in 25% of patients after documented endoscopic 
resolution on a subsequent EGD. Historically, APC 
has been reported to have > 80% success rate for 
treatment of anemia or GI bleeding related to GAVE. 
However, most of these case series did not evaluate 
endoscopic resolution or recurrence of GAVE[1-7].
Findings in this study support the low success rate 
of APC in the treatment of GAVE related anemia or GI 
bleeding as reported by Boltin et al[7] and Swanson et 
al[8]. It would be empirically expected that endoscopic 
appearance of GAVE would correlate with improvement 
in GAVE-related anemia or GI bleeding. Therefore, if the 
70% rate of combined endoscopic non-resolution and 
recurrence seen in this series is correct, then APC would 
be expected to show suboptimal rates of improvement 
in GAVE-related symptoms. 
There are several possible reasons for the low 
success rate of APC in endoscopic resolution of GAVE. 
GAVE varies significantly in morphology (flat vs nodular) 
Patients with 
cirrhosis 
(n  = 16)
Patients 
without 
cirrhosis
 (n  = 4)
P  value
  Median age (range) in years   59.5 (42-74) 62.5 (53-73) 0.51
  Males     9 (56.3) 1 (25) 0.58
  Caucasians   16 (100)   4 (100) -
  Indication for initial EGD -
     Upper gastrointestinal tract 
     bleeding
    7 (43.7) 2 (50)
     Iron deficiency anemia     5 (31.3) 1 (25)
     Esophageal varices screening or 
     surveillance
 4 (25) -
     Follow up of arteriovascular 
     malformations
- 1 (25)
  Median number of APC sessions 
  (range)
  2 (1-7)     2.5 (1-6) 0.66
  Endoscopic resolution of GAVE  8 (50) 0 0.12
  Recurrence of GAVE 2/8 (25%) - -
Table 1  Demographic features of patients with symptomatic 
gastric antral vascular ectasia  n  (%)
APC: Argon plasma coagulation; EGD: Esophagogastroduodenoscopy; 
GAVE: Gastric antral vascular ectasia.
  No. of APC 
  sessions
No. of total 
patients
Patients with GAVE 
resolution (%)
P  value
  1   7 2 (29) 0.33
  2   5 2 (40)
  3   3 1 (33)
  4-7   5 3 (60)
  Total 20 8 (40)
Table 2  Eradication success rate by number of argon plasma 
coagulation treatment sessions
APC: Argon plasma coagulation; GAVE: Gastric antral vascular ectasia.
Garg S et al . GAVE resolution with APC treatment
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and severity (striped distribution in the antrum vs diffuse 
involvement of antral mucosa) between patients. APC 
may not work with similar effectiveness in all these 
situations. Additionally, the abnormal dilated capillaries 
and fibromuscular hyperplasia in GAVE extend to the 
lamina propria[9]. However, the coagulation effect of APC 
rarely (4.8%) ablates the entire thickness of lamina 
propria. Moreover, coagulation of the entire thickness 
of the lamina propria needs power of 90-Watts or 
more which is significantly higher than the usual power 
settings (30-80 W) used to treat GAVE [4,7,10].
There are some limitations of this study. The study 
has a small sample size. It is retrospective in nature and 
does not have a control group or a second intervention 
group to compare the outcomes with APC treatment. 
The study did not follow a defined program of conse-
cutive APC sessions to achieve GAVE eradication, nor 
was there a defined surveillance protocol to search for 
recurrence. However, the lack of correlation between 
number of APC sessions and treatment success in 
this study suggests that this might not be an effective 
modality even in principle, or might require an excessive 
number of APC sessions. A prospective, protocol-driven 
study will be needed to resolve these questions.
In summary, APC may not be an effective therapy 
in long term for the treatment of symptomatic GAVE. 
Alternate therapies including radiofrequency ablation 
and/or banding should be evaluated in a prospective, 
randomized fashion against APC in order to determine 
the appropriate endoscopic approach for the treatment 
of symptomatic GAVE. 
COMMENTS
Background
Argon plasma coagulation (APC) is the most widely used treatment method for 
gastric antral vascular ectasia (GAVE). However, a recent systematic review 
reported 44%-50% recurrence rate of symptoms related to GAVE after treatment 
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GAVE after therapy with APC.
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with APC and its recurrence rate after successful treatment with APC therapy.
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with only 40% resolution of GAVE as evaluated by endoscopy. Out of these 
40% cases, GAVE was noted to recur during a subsequent esophago-
gastroduodenoscopy (EGD) in 25% of cases. The resolution of GAVE was not 
associated with number of APC sessions performed to treat GAVE.
Applications
The results of this study suggest that APC may not be an effective therapy in 
long term for the treatment of symptomatic GAVE. Alternate therapies including 
radiofrequency ablation and/or banding should be evaluated in a prospective, 
randomized fashion against APC in order to determine the appropriate 
endoscopic approach for the treatment of symptomatic GAVE.
Terminology
GAVE is a distinct clinical entity characterized endoscopically by prominent flat 
or erythematous streaks radiating in a spoke-like fashion from the pylorus to 
the antrum and pathologically by spindle cell proliferation in the mucosal blood 
vessels, intravascular fibrin thrombi and fibrinohyalinosis. EGD is a procedure 
used to examine the upper gastrointestinal tract (from esophagus to forth part 
of duodenum) using a flexible video endoscope. APC is a type of non-contact 
thermal therapy used during EGD to obtain hemostasis or tissue destruction. It 
involves infusion of argon gas through a catheter into the lumen of gastrointestinal 
tract. The gas is converted into plasma by passing electricity through the catheter. 
The plasma then conducts the electricity to the tissue to achieve hemostasis or 
tissue destruction. The catheter does not come into direct contact with the tissue.
Peer-review
The authors have looked into the outcomes of 20 patients with GAVE who underwent 
endoscopic APC treatment and concluded that endoscopic resolution rate of GAVE 
was low (40%) with a 25% recurrence rate after treatment with APC. The manuscript 
is interesting and provided some insight on the treatment of GAVE using APC.
REFERENCES
1 Sebastian S, McLoughlin R, Qasim A, O’Morain CA, Buckley MJ. 
Endoscopic argon plasma coagulation for the treatment of gastric 
antral vascular ectasia (watermelon stomach): long-term results. 
Dig Liver Dis 2004; 36: 212-217 [PMID: 15046192 DOI: 10.1016/
j.dld.2003.11.028]
2 Chiu YC, Lu LS, Wu KL, Tam W, Hu ML, Tai WC, Chiu 
KW, Chuah SK. Comparison of argon plasma coagulation in 
management of upper gastrointestinal angiodysplasia and gastric 
antral vascular ectasia hemorrhage. BMC Gastroenterol 2012; 12: 
67 [PMID: 22681987 DOI: 10.1186/1471-230x-12-67]
3 Yusoff I, Brennan F, Ormonde D, Laurence B. Argon plasma 
coagulation for treatment of watermelon stomach. Endoscopy 2002; 
34: 407-410 [PMID: 11972274 DOI: 10.1055/s-2002-25287]
4 Roman S, Saurin JC, Dumortier J, Perreira A, Bernard G, Ponchon 
T. Tolerance and efficacy of argon plasma coagulation for controlling 
bleeding in patients with typical and atypical manifestations of 
watermelon stomach. Endoscopy 2003; 35: 1024-1028 [PMID: 
14648415 DOI: 10.1055/s-2003-44594]
5 Lecleire S, Ben-Soussan E, Antonietti M, Goria O, Riachi G, 
Lerebours E, Ducrotté P. Bleeding gastric vascular ectasia treated by 
argon plasma coagulation: a comparison between patients with and 
without cirrhosis. Gastrointest Endosc 2008; 67: 219-225 [PMID: 
18226684 DOI: 10.1016/j.gie.2007.10.016]
6 Herrera S, Bordas JM, Llach J, Ginès A, Pellisé M, Fernández-
Esparrach G, Mondelo F, Mata A, Cárdenas A, Castells A. The 
beneficial effects of argon plasma coagulation in the management of 
different types of gastric vascular ectasia lesions in patients admitted 
for GI hemorrhage. Gastrointest Endosc 2008; 68: 440-446 [PMID: 
18423466 DOI: 10.1016/j.gie.2008.02.009]
7 Boltin D, Gingold-Belfer R, Lichtenstein L, Levi Z, Niv Y. Long-term 
treatment outcome of patients with gastric vascular ectasia treated 
with argon plasma coagulation. Eur J Gastroenterol Hepatol 2014; 26: 
588-593 [PMID: 24743501 DOI: 10.1097/meg.0000000000000047]
8 Swanson E, Mahgoub A, MacDonald R, Shaukat A. Medical and 
endoscopic therapies for angiodysplasia and gastric antral vascular 
ectasia: a systematic review. Clin Gastroenterol Hepatol 2014; 12: 
571-582 [PMID: 24013107 DOI: 10.1016/j.cgh.2013.08.038]
9 Gilliam JH, Geisinger KR, Wu WC, Weidner N, Richter JE. 
Endoscopic biopsy is diagnostic in gastric antral vascular ectasia. 
The “watermelon stomach”. Dig Dis Sci 1989; 34: 885-888 [PMID: 
2721320]
10 Watson JP, Bennett MK, Griffin SM, Matthewson K. The tissue 
effect of argon plasma coagulation on esophageal and gastric 
mucosa. Gastrointest Endosc 2000; 52: 342-345 [PMID: 10968847 
DOI: 10.1067/mge.2000.108412]
P- Reviewer: Chai FY     S- Editor: Gong ZM    L- Editor: A    E- Edi-
tor: Wu HL
 COMMENTS
Garg S et al . GAVE resolution with APC treatment
© 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
